Providing Groceries and Transportation to Poverty-Exposed Pediatric Oncology Families
Haley Newman,Emily Jones,Yimei Li,Puja J. Umaretiya,Julie A. Wolfson,Joanne Wolfe,Kira Bona
DOI: https://doi.org/10.1001/jamanetworkopen.2024.12890
2024-06-01
JAMA Network Open
Abstract:Poverty is independently associated with childhood cancer relapse and death. 1 ,2 To date, no evidence-based interventions targeting poverty as a risk factor for poor outcome have been evaluated in pediatric oncology. We evaluated central administration of the Pediatric Cancer Resource Equity (PediCARE) intervention, 3 which provided groceries and transportation to poverty-exposed pediatric oncology families. The trial aimed to assess feasibility data necessary to inform randomized efficacy trials, including (1) caregiver willingness to be randomized to a poverty-targeted intervention and (2) attrition among participants randomized to standard of care. This pilot randomized clinical trial of usual supportive care (control) vs usual supportive care plus PediCARE (intervention) included participants at Dana-Farber Cancer Institute (DFCI; Boston, Massachusetts) and University of Alabama at Birmingham (UAB) enrolled between May 2019 and August 2021. Children aged 0 to 17 years within 2 months of a de novo cancer diagnosis with planned receipt of at least 4 cycles of chemotherapy were eligible if their parent and/or guardian self-reported household material hardship (HMH), defined as at least 1 domain of food, housing, utility, or transportation insecurity. Parent and/or guardians provided consent for study enrollment on behalf of their children. This study was approved by the DFCI institutional review board (IRB), which served as the central IRB for both enrolling institutions, and was registered on ClinicalTrials.gov (NCT03638453). This report follows the CONSORT reporting guideline for pilot or feasibility randomized trials. Participants were randomized 1:1, stratified by site, to control vs intervention for 6 months. Intervention participants received PediCARE, a centrally administered standardized allocations of groceries via the Instacart online grocery-delivery platform, and transportation via patient-scheduled ride-share or gas cards, in addition to usual supportive care. Participation included baseline and 6-month parent and/or guardian surveys. Trial protocol, statistical design, and surveys are provided in Supplement 1. Additional methods are shown in the eAppendix in Supplement 2. The primary study end point was feasibility, defined as more than 75% consent to randomization or participation, and less than 20% attrition (study withdrawal or incomplete 6-month time point survey) per group. Among 41 families (28 at DFCI and 13 at UAB) (Table), 100% consented to enrollment and randomization; 1 patient at UAB was subsequently deemed ineligible (Figure). There was 0% attrition in either group, and 100% baseline and 6-month survey completion. All intervention participants successfully received grocery and/or transportation resources. A greater proportion of intervention participants experienced stabilized (no change) or decreased numbers of HMH domains at 6 months vs control (17 participants [85%] vs 14 participants [70%]). More intervention than control participants reported no HMH at 6 months (5 participants [25%] vs 2 participants [10%]). In this randomized clinical trial, 100% of participants consented to randomization with 0% attrition in either group. These data demonstrate caregiver recognition of the need for evidence-based interventions to address poverty during childhood cancer treatment and a willingness to participate in randomized research to evaluate such interventions. We successfully enrolled a population of families facing multiple social risks, supporting the feasibility of health equity intervention evaluation among historically marginalized subspecialty populations. Equally important, we demonstrate the feasibility of a centrally delivered intervention a priori designed for scalability. Owing to the rarity of childhood cancer, most US children receive treatment via multicenter clinical drugs trials that accrue at more than 200 centers to achieve adequate samples sizes for statistical power. 4 Evaluation of disease-specific health equity intervention efficacy in pediatric oncology can only be accomplished in this multicenter trial setting, requiring interventions designed to scale with minimal site burden. This pilot study was unable to detect statistically significant differences in HMH between arms. Although it was conducted in hospitals in diverse geographic settings, feasibility findings may not be generalizable to all sites of pediatric oncology care. One in 3 children with cancer is exposed to poverty, 5 ,6 and these children are more likely to relapse and die. Ensuring equity in pediatric oncology requires evaluation of novel interventions targeting this independent risk factor. These data lay the groundwork for systematic incorporation of poverty-targeted interventions in future pediatric oncology trials. Accepted for Publication: March 22, 2024. P -Abstract Truncated-
medicine, general & internal